Managing Miscarriage

Managing Miscarriage

Guides miscarriage evaluation with definitive ultrasound diagnostic criteria, β-hCG correlation, and evidence-based management options per ACOG Practice Bulletin No. 200 and the 2012 SRU Consensus.

Why This Skill Exists

Early pregnancy loss (miscarriage) occurs in 10–15% of clinically recognized pregnancies, making it the most common complication of pregnancy. The 2012 Society of Radiologists in Ultrasound (SRU) consensus conference established strict ultrasound criteria for diagnosing pregnancy failure to prevent iatrogenic termination of a viable pregnancy — a catastrophic error. Before these criteria, more liberal cutoffs led to documented cases of intervention on pregnancies that would have been viable.

ACOG Practice Bulletin No. 200 (Early Pregnancy Loss) outlines three management options — expectant, medical, and surgical — each with specific indications, success rates, and follow-up requirements. Proper documentation of diagnostic certainty before offering management is both a clinical and medicolegal imperative.

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Gestational age — by LMP and/or prior ultrasound dating? (Default: from chart)
2. Symptoms — vaginal bleeding (amount, duration, clots), cramping, passage of tissue? (Default: from chief complaint)
3. Ultrasound findings — CRL, gestational sac mean diameter, yolk sac, fetal cardiac activity? (Default: from current US report)
4. β-hCG values — serial levels with dates? (Default: from lab results)
5. Pregnancy desire — was this a desired pregnancy? (Default: assess for emotional support needs)
6. Rh status — RhoGAM needed if Rh-negative? (Default: from prenatal or current labs)
7. Prior pregnancy losses — number of prior miscarriages? (If ≥ 3, evaluate for recurrent pregnancy loss.) (Default: from OB history)
8. Medical history — coagulopathy, antiphospholipid syndrome, uterine anomalies, thyroid disease? (Default: from problem list)

Documents to Request

• Transvaginal ultrasound reports (current and prior — need comparison for interval change)
• Serial β-hCG values with dates and times
• Prior obstetric records (history of prior losses)
• Blood type and Rh status
• CBC (assess for significant blood loss)
• Pathology reports (if tissue passed or obtained from prior procedures)
• Recurrent pregnancy loss workup results (if applicable)

Step 1: Apply Definitive Ultrasound Diagnostic Criteria

Per the 2012 SRU Consensus and ACOG, pregnancy failure is diagnosed when ANY of the following are met:

Diagnostic (Definitive) Criteria for Pregnancy Failure

Suspicious (Indeterminate) Findings — Require Follow-Up

CRITICAL: When findings are indeterminate, do NOT intervene. Repeat imaging in 7–14 days.

Step 2: Classify the Type of Pregnancy Loss

Document the classification with supporting ultrasound and clinical findings.

Step 3: Management Options

Per ACOG Practice Bulletin No. 200, present three options after confirmed pregnancy failure:

Expectant Management

• Allow spontaneous passage of products
• Success rate: 80% within 8 weeks for anembryonic, 65–85% for embryonic demise
• Best when: patient prefers to avoid medication/procedures, no signs of infection, hemodynamically stable
• Follow-up: β-hCG in 7–14 days to confirm decline; repeat US if no passage by 4 weeks
• Return precautions: heavy bleeding (soaking > 2 pads/hour × 2 hours), fever, foul-smelling discharge

Medical Management (Misoprostol)

• Dosing: Misoprostol 800 mcg vaginally (with or without mifepristone 200 mg PO 24 hours prior)
• Mifepristone pretreatment improves success rate from ~67% to ~84% (per ACOG)
• May repeat misoprostol dose at 24–48 hours if no passage
• Follow-up: US in 7–14 days to confirm complete passage; β-hCG to confirm decline
• Analgesic plan: ibuprofen 600 mg + opioid rescue if needed (acetaminophen with codeine or oxycodone)

Surgical Management (Uterine Aspiration)

• Suction curettage (manual vacuum aspiration or electric vacuum aspiration)
• Success rate: > 99%
• Indications for surgical preference: heavy bleeding, signs of infection, patient preference, need for tissue for karyotype (recurrent loss workup)
• Confirm products of conception on pathology (presence of villi)
• Antibiotics: doxycycline 200 mg PO before procedure (prophylaxis per ACOG)

Step 4: Post-Miscarriage Care and Counseling

1. Rh immunoglobulin — administer RhoGAM 50 mcg (if < 12 weeks) or 300 mcg (if ≥ 12 weeks) to all Rh-negative patients
2. Emotional support — acknowledge the loss, screen for grief reaction, provide resources, offer counseling referral
3. Contraception — discuss timing of future conception; ovulation can occur as early as 2 weeks post-miscarriage
4. Future pregnancy counseling — risk of recurrent loss after 1 miscarriage is 15–20% (similar to baseline); after 2 losses, ~25%; after 3 losses, ~30–40%
5. Recurrent pregnancy loss (RPL) workup — indicated after 2–3 consecutive losses:
   • Antiphospholipid antibody panel (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2 glycoprotein I IgG/IgM) — repeat in 12 weeks if positive
   • Parental karyotype (balanced translocation)
   • Uterine cavity evaluation (SIS or hysteroscopy for septum, Asherman)
   • TSH, prolactin
   • Products of conception karyotype (if tissue available)

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Are definitive SRU criteria met before diagnosing pregnancy failure — CRL ≥ 7 mm with no cardiac activity or MSD ≥ 25 mm with no embryo?
2. Is the type of pregnancy loss classified with supporting evidence?
3. Are all three management options presented with success rates and follow-up requirements?
4. Is Rh status addressed and RhoGAM documented?
5. Is emotional support and future pregnancy counseling documented?

Quality Audit

• Definitive ultrasound criteria applied (SRU 2012 / ACOG thresholds) before diagnosing failure
• Indeterminate findings flagged for repeat imaging (NOT treated as diagnosed failure)
• Type of pregnancy loss classified (threatened, inevitable, incomplete, complete, missed, anembryonic)
• β-hCG values documented with trend
• All three management options discussed (expectant, medical, surgical)
• Selected management documented with dosing (misoprostol) or procedure details (aspiration)
• Analgesic plan documented for medical management
• Follow-up plan documented (β-hCG monitoring, repeat US timing)
• Return precautions provided (heavy bleeding thresholds, fever, foul discharge)
• Rh status documented and RhoGAM administered/planned
• Pathology of POC documented (surgical cases — confirm chorionic villi)
• Emotional support offered and documented
• Recurrent pregnancy loss workup addressed (if ≥ 2 prior losses)
• Contraception and interpregnancy counseling documented

Guidelines

1. Never diagnose pregnancy failure below the SRU thresholds — CRL must be ≥ 7 mm (not 5 mm) for definitive diagnosis of no cardiac activity. Using lower thresholds risks terminating a viable pregnancy.
2. When in doubt, wait — if findings are indeterminate, repeat the ultrasound in 7–14 days. There is no harm in waiting; there is irreversible harm in acting on an incorrect diagnosis.
3. Mifepristone + misoprostol is superior to misoprostol alone for medical management — offer the combined regimen when mifepristone is available.
4. Respect patient preference — all three management options (expectant, medical, surgical) are medically appropriate for uncomplicated early pregnancy loss; the patient's choice should drive the decision.
5. Always confirm tissue passage — after medical or expectant management, follow β-hCG to < 5 IU/L and obtain ultrasound confirmation of empty uterus to rule out ectopic.
6. Send tissue for karyotype in recurrent loss — products of conception cytogenetics identifies aneuploidy as the cause in ~50–60% of sporadic losses and guides further workup.
7. Screen for antiphospholipid syndrome after recurrent loss — it is the most treatable cause of RPL (treatment with aspirin + heparin reduces loss rate from 54% to 25%).
8. Use compassionate language — in documentation and communication, use "pregnancy loss" or "miscarriage" rather than "spontaneous abortion," which is distressing to patients.